Literature DB >> 10836614

Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis.

O Hardiman1.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by death of upper and lower motor neurones. Nutritional and respiratory failure occurs in most patients with ALS. Nutritional failure occurs primarily as a result of dysphagia, although malnutrition may also develop in the absence of clinically apparent dysphagia. The optimal management of nutrition in early ALS has not been established. In later stages of the disease, parenteral nutritional support using percutaneous endoscopic gastrostomy confers a significant survival benefit in selected patients. Respiratory failure occurs as a result of bulbar, cervical and thoracic loss of motor neurones. Inspiratory muscles are preferentially affected. Management of respiratory failure includes the use of strategies that limit aspiration pneumonia, the reduction in secretions, and positioning of the patient to a maximal mechanical advantage. Use of non-invasive positive pressure ventilation in appropriate patients significantly enhances survival. The decision to undertake invasive mechanical ventilation should be made prior to the development of symptoms that might warrant this intervention. The progressive nature of the condition should be taken into account when such a decision is discussed with the patient and carer. Further studies are required to determine the optimal nutritional requirements of patients with ALS, and to elucidate the physiological changes involved in the decline in respiratory function.

Entities:  

Mesh:

Year:  2000        PMID: 10836614     DOI: 10.1007/s004150050578

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  9 in total

Review 1.  Management of motor neurone disease.

Authors:  R S Howard; R W Orrell
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

Review 2.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

3.  Outcome of ventilatory support for acute respiratory failure in motor neurone disease.

Authors:  M D Bradley; R W Orrell; J Clarke; A C Davidson; A J Williams; D M Kullmann; N Hirsch; R S Howard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 4.  Nutrition and dietary supplements in motor neuron disease.

Authors:  Jeffrey Rosenfeld; Amy Ellis
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-08       Impact factor: 1.784

5.  Nutritional support teams increase percutaneous endoscopic gastrostomy uptake in motor neuron disease.

Authors:  Lin Zhang; Leanne Sanders; Robert J L Fraser
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

6.  Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.

Authors:  Richard Smith; Erik Pioro; Kathleen Myers; Michael Sirdofsky; Kimberly Goslin; Gregg Meekins; Hong Yu; James Wymer; Merit Cudkowicz; Eric A Macklin; David Schoenfeld; Gary Pattee
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

7.  Epidural anesthesia combined with sedation with dexmedetomidine for appendectomy in a patient with amyotrophic lateral sclerosis: a case report.

Authors:  Mikako Kusakai; Atsushi Sawada; Natsumi Kii; Yasuyuki Tokinaga; Naoyuki Hirata; Michiaki Yamakage
Journal:  JA Clin Rep       Date:  2018-12-26

Review 8.  The Benefit of Non-invasive Ventilation in Motor Neuron Disease.

Authors:  Laura J Walsh; Desmond M Murphy
Journal:  Open Respir Med J       Date:  2020-12-15

9.  Use of non-invasive ventilation in motor neuron disease - a retrospective cohort analysis.

Authors:  Laura J Walsh; Kevin F Deasy; Fernando Gomez; Elizabeth O'Sullivan; Joseph Eustace; Aisling M Ryan; Desmond M Murphy
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 3.115

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.